businesspress24.com - Trimel Pharmaceuticals Corporation to Report Second Quarter 2012 Results and Host a Conference Call
 

Trimel Pharmaceuticals Corporation to Report Second Quarter 2012 Results and Host a Conference Call to Update Investors

ID: 1138647

(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 08/01/12 -- Trimel Pharmaceuticals Corporation (TSX: TRL) (the "Company" or "Trimel") will report on the second quarter financial results for the Company and its subsidiaries for the period ended June 30, 2012 on Tuesday August 7, 2012 after the market closes.

Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Wednesday, August 8, 2012, at 8:30 a.m. Eastern Daylight Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, Tom Rossi, President and Chief Operating Officer and Kenneth Howling, Chief Financial Officer.

To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Time on Tuesday, August 14, 2012 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 2484026#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at .

About Trimel

Trimel Pharmaceuticals Corporation (TSX: TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit .



Contacts:
Trimel Pharmaceuticals Corporation




Kenneth G. Howling
Chief Financial Officer
416 679 0536


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  American Health Extends Population Health Management Services to Enhance Member Wellness Resources
Portola Appoints Robert M. Califf, M.D., to Board of Directors
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 01.08.2012 - 13:21 Uhr
Sprache: Deutsch
News-ID 1138647
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Healthcare


Anmerkungen:


Diese Pressemitteilung wurde bisher 134 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Trimel Pharmaceuticals Corporation to Report Second Quarter 2012 Results and Host a Conference Call to Update Investors
"
steht unter der journalistisch-redaktionellen Verantwortung von

Trimel Pharmaceuticals Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Trimel Pharmaceuticals Corporation



 

Who is online

All members: 10 578
Register today: 0
Register yesterday: 4
Members online: 0
Guests online: 95


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.